CONTINUATION APPLICATION

For

UNITED STATES LETTERS PATENT

on

METHOD FOR PRODUCING AND IMPROVING THERAPEUTIC POTENCY OF BINDING POLYPEPTIDES

by

William D. Huse

Attorneys

McDermott, Will & Emery
4370 La Jolla Village Drive, Suite 700
San Diego, California 92122

METHODS FOR PRODUCING AND IMPROVING THERAPEUTIC POTENCY
OF BINDING POLYPEPTIDES

This application is based on, and claims the benefit of, U.S. Provisional Application No. 60/_____,
5 filed October 30, 2000, which was converted from U.S. Serial No. 09/702,140, and which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

The present invention relates generally to the
10 treatment of disease and more specifically to binding molecules useful as therapeutics.

Modern medicine benefits from increased manipulation of molecular level interactions that mediate individual diseases. This is especially the case for
15 treatment of disease and disease symptoms with drug therapies. The drug development industry uses strategies based on molecular level analysis in attempting to develop therapeutically effective drugs.

One such strategy, used in the drug development
20 industry, is to identify a target molecule associated with a disease and to produce a drug that binds to the target molecule to either block the target molecule's activity or to deliver a toxic payload to the site where the target molecule resides in the diseased individual.
25 Under such a strategy, the discovery phase of research utilizes *in vitro* methods to identify a lead drug candidate that binds to a target molecule. The lead drug candidate can then be entered into the validation phase

of research where *in vivo* tests are performed to
determine if the lead drug candidate demonstrates
therapeutic effectiveness.

5   Two commonly used discovery phase approaches are
structure based drug design and screening a pool of
candidate molecules. Structure based drug design uses
the target molecule's three dimensional structure, or
other structure-related property, as a template to which
10 drug candidates are fit to identify a structural model
for a lead drug candidate. The lead drug candidate is
then synthesized and tested *in vitro*. Alternatively,
screening uses an isolated target molecule to select a
lead drug candidate from a large population of drug
15 candidates *in vitro*. One factor in both approaches is
exploitation of the stability of the binding interaction
between the target molecule and lead drug candidate. In
this regard a large number of structure based design
algorithms are aimed at identifying a lead drug candidate
20 that docks with the target molecule to form a stable
complex and a large number of screens are designed to
select lead drug candidates that form a stable binding
complex with the target molecule.

Genomics, protein engineering and combinatorial
25 chemistry have been used to identify targets and
potential drug candidates that are input into the *in
vitro* methods of discovery phase research. These and
other methods may allow high throughput identification
and production of therapeutic drugs leading to increases
30 in both the number of disease targets and the number of
lead drug candidates.

Unfortunately, the production of therapeutic drugs has not improved in a correlative fashion with improvements in methods of discovery phase approaches or the greater number and variety of discovery phase inputs.

5　In particular, the identified lead drug candidates too often fail to demonstrate therapeutic effectiveness. Diversion of resources to an unsuccessful drug candidate in the validation phase can be costly because millions of dollars and numerous years can be wasted on a failed lead

10　drug candidate. More importantly, those suffering from devastating diseases are deprived of a treatment or cure.

Thus, there exists a need for a rapid and efficient method which accurately predicts successful

15　lead drug candidates exhibiting therapeutic effectiveness against a disease. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The invention provides a binding polypeptide, or

20　functional fragment thereof, comprising a k_{on} of at least about 9×10^7 $M^{-1}s^{-1}$ for associating with a ligand and having therapeutic potency. The invention also provides a method of determining the therapeutic potency of a binding polypeptide. The methods consist of (a)

25　contacting a binding polypeptide with a ligand; (b) measuring association rate for binding between the binding polypeptide and the ligand, and (c) comparing the association rate for the binding polypeptide to an association rate for a therapeutic control, the relative

30　association rate for the binding polypeptide compared to the association rate for the therapeutic control

indicating that the binding polypeptide will exhibit a difference in therapeutic potency correlative with the difference between the association rates.

DETAILED DESCRIPTION OF THE INVENTION

5   The invention is directed to the discovery that the therapeutic potency of a molecule correlates with the rate at which the therapeutic molecule associates with a ligand that mediates or correlates with a pathological condition. The invention provides a binding polypeptide,
10   or functional fragment thereof, having a k_{on} of at least about 9×10^7 $M^{-1}s^{-1}$ for associating with a ligand and having therapeutic potency. The invention further provides a grafted antibody, or functional fragment thereof, having a k_{on} of at least about 1.3×10^6 $M^{-1}s^{-1}$ to
15   a ligand and having therapeutic potency.

      In one embodiment the methods of the invention allow for accurate *in vitro* prediction and identification of molecules having therapeutic potency. In one embodiment the methods involve determining the
20   therapeutic potency of a binding polypeptide by comparing the association rate for the binding polypeptide to an association rate for a therapeutic control. The binding polypeptide will exhibit a difference in therapeutic potency correlative with the difference between said
25   association rates. In another embodiment, the methods of the invention involve identifying therapeutic potency of a binding polypeptide by identifying a binding polypeptide exhibiting a high association rate or k_{on}, correlating with its therapeutic potency. The methods of
30   the invention can also be used to change the structure

and ligand binding activity of a parent polypeptide to create one or more progeny polypeptides, and to identify progeny polypeptides that are binding polypeptides having improved therapeutic potency resulting from increased
5   association rate with a ligand.

An advantage of the invention is that a binding polypeptide having improved therapeutic potency can be distinguished from a binding polypeptide that has an increased K_a for a ligand but not improved therapeutic
10 potency. A further advantage of the methods of the invention is that a means to screen large numbers of potential therapeutic molecules *in vitro* is provided, thereby increasing the rate and efficiency of identifying effective therapeutics while reducing the costs
15 associated with *in vivo* testing of failed therapeutics.

As used herein, the term "binding polypeptide" refers to a polymer of amino acids that selectively associates with a ligand. A binding polypeptide can have, for example, at least 2, 5, 8, 10, 12, 15, 20, 25,
20 50, 100, 200 or 400 or more amino acids so long as the polypeptide retains ability to associate with a ligand. Therefore, the term binding polypeptide, as used herein, includes all sizes of amino acid polymers ranging from a couple to hundreds or even thousands of amino acids.

25   A binding polypeptide can be a naturally occurring polypeptide, for example, a receptor, enzyme or hormone. A receptor can include, for example, an immunoglobulin, such as an antibody or T cell receptor; integrin; hormone receptor; lectin; membrane receptor; or transmitter
30 receptor. An enzyme can include, for example, a

protease, oxidoreductase, kinase, lipase, phosphatase, DNA modifying enzyme, polymerase, caspase, transcription factor, GTPase, ATPase, or a membrane channel. A hormone can include for example, a growth factor, insulin,

5 cytokine, neural peptide, extracellular matrix protein or clotting factor. A binding polypeptide can be a modified form of a naturally occurring polypeptide, for example, a fragment, chimera containing amino acids from a donor polypeptide, or fusion of fragments from one or more

10 donor polypeptides so long as such polypeptide retains ability to associate with a ligand.

A binding polypeptide can be a polypeptide that contains a non-naturally occurring moiety including, for example, an amino acid derivative, sterioisomer of an

15 amino acid, amino acid analogue or functional mimetic of an amino acid. For example, a derivativea can include a chemical modification of the polypeptide such as alkylation, acylation, carbamylation, iodination, or any modification which derivatizes the polypeptide. An

20 analogue can include a modified amino acid, for example, hydroxyproline or carboxyglutamate, and can include an amino acid that is not linked by a peptide bond. Mimetics encompass a molecule containing a chemical moiety that mimics the function of the polypeptide

25 regardless of a difference in three-dimensional structure between the binding polypeptide and mimetic. For example, if a polypeptide contains two charged chemical moieties in a functional domain, a mimetic can place two charged chemical moieties in a spatial orientation and

30 constrained structure so that the relative location of the charged chemical moieties is maintained in

three-dimensional space independent of any other
differences between the polypeptide and mimetic.

As used herein, the term "ligand" refers to a
small molecule, compound or macromolecule that can
5 selectively associate with a binding polypeptide. A
ligand can be a naturally occurring molecule, compound or
macromolecule including, for example, DNA, RNA,
polypeptide, lipid, carbohydrate, amino acid, nucleotide
or hormone. A ligand can be a derivative of a naturally
10 occurring molecule, compound or macromolecule resulting
in, for example, an added moiety, a removed moiety or a
rearrangement in the relative location of moieties.
Examples of added moieties include, for example, a
biotin, peptide such as polyhistidine, radioisotope or
15 chemically reactive group capable of forming a covalent
bond to a second molecule. A ligand can be a mimetic of
naturally occurring molecule, compound or macromolecule.
Mimetics encompass molecules containing chemical moieties
that mimic the function of the ligand regardless of
20 differences between three-dimensional structure of the
mimetic and the ligand. A mimetic can be, for example, a
synthetically prepared molecule or a polypeptide
containing a modified form of a naturally occurring amino
acid. A ligand can be an antigen found on a cell such as
25 a cancer cell, microbe, bacteria, fungus or virus. A
ligand can also be a molecule that is a toxic substance.

As used herein, the term "parent polypeptide"
refers to a polymer of amino acids that can be changed to
produce a binding polypeptide. Therefore, a parent
30 polypeptide is the molecule to be improved using the
methods of the invention. As used herein a parent

polypeptide can have, for example, at least 2, 5, 8, 10, 12, 15, 20, 25, 50, 100, 200 or 400 or more amino acids. Therefore, the term parent polypeptide, as used herein, includes all sizes of amino acid polymers ranging from a couple to hundreds or even thousands of amino acids.

A parent polypeptide can be a naturally occurring polypeptide, for example, a receptor, enzyme or hormone such as those described above in reference to a binding polypeptide. A parent polypeptide can be a polypeptide that contains a non-naturally occurring moiety including, for example, an amino acid derivative, a sterioisomers of an amino acid, an amino acid analogue or a functional mimetic of an amino acid such as those described above in reference to a binding polypeptide.

As used herein the term "progeny polypeptide" refers to a polymer of amino acids that has different structure compared to the parent polypeptide from which it was produced. A different structure can include, for example, addition, deletion, substitution or chemical modification of one or more amino acids. A progeny polypeptide can be a different species from the parent polypeptide. A progeny polypeptide can associate with a ligand at the same or different association rate compared to the association rate at which its parent polypeptide associates with the same ligand. As used herein a progeny polypeptide can have, for example, at least 2, 5, 8, 10, 12, 15, 20, 25, 50, 100, 200 or 400 or more amino acids. Therefore, the term progeny polypeptide, as used herein, includes all sizes of amino acid polymers ranging from a couple to hundreds or even thousands of amino acids.

A progeny polypeptide can be a modified form of a parent polypeptide, for example, a fragment, chimera containing amino acids from a donor polypeptide, or fusion of fragments from one or more donor polypeptide. A progeny polypeptide can be a polypeptide that contains a non-naturally occurring moiety including, for example, an amino acid derivative, sterioisomer of an amino acid, amino acid analogue or functional mimetic of an amino acid such as those described above.

As used herein, the term "grafted" when used in reference to an antibody, or functional fragment thereof, refers to an antibody, or functional fragment thereof, having a variable region acceptor framework from one species containing one or more CDR from a donor or second species. One skilled in the art will know that the function of an antibody, or functional fragment thereof, can be influenced by a change in a single CDR or more preferably in multiple CDRs. Amino acids can be added, deleted or substituted at any position in the acceptor framework or donor CDRs and can include, for example, changes that modify structure or function of the grafted antibody, or functional fragment thereof, whether minor or significant so long as the antibody, or functional fragment thereof, contains a variable region acceptor framework from one species and at least one CDR from another species. Description of grafted antibodies and methods for their production are well known in the art and are described, for example, in U.S. Patent No. 5,225,539; "Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man," Clark, M. (ed.), Nottingham, England: Academic Titles (1993); Winter and Harris, Immunol. Today, 14:243-246 (1993);

Winter and Harris, Tips, 14:139-143 (1993) and Couto et al. Cancer Res., 55:1717-1722 (1995) which are incorporated herein by reference.

As used herein, the term "functional fragment," when used in reference to a binding polypeptide, is intended to refer to a portion of a binding polypeptide which retains the ability to selectively associate with a ligand. Functional fragments can include dissociated subunits of a binding polypeptide, for example, individual heavy or light chains of an antibody. Functional fragments can include portions of a binding polypeptide having a reduced number of amino acids, for example, Fd, Fab or $F(ab)_2$ portions of an antibody. Functional fragments can include portions of a dissociated subunits of a binding polypeptide having a reduced number of amino acids including, for example, Fv, V_H, a CDR, or scFv portions of an antibody. Such terms are described in, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989); Molec. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, R.A. (ed.), New York: VCH Publisher, Inc.); Huston et al., Cell Biophysics, 22:189-224 (1993); Plückthun and Skerra, Meth. Enzymol., 178:497-515 (1989) and in Day, E.D., Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc., New York, NY (1990), which are incorporated herein by reference. Thus, a functional fragment can include an immunologically active portion, fragment or segment of an antibody.

A functional fragment of a binding polypeptide can have minor structural differences in comparison to a full

length binding polypeptide so long as the fragment has
about the same structure as the corresponding region of
the full length binding polypeptide and retains the
ability to selectively associate with a ligand. Minor

5 structural differences can be at the primary, secondary,
tertiary, or quaternary sequence level. Structural
differences at the primary sequence level include changes
in the amino acid sequence and can be, for example,
additions, deletions or substitutions of amino acids or

10 chemical modifications of amino acids, such as addition
of a chemical moiety, so long as such a polypeptide
retains the ability to associate with a ligand. An added
moiety can include, for example, a chemically derivatized
amino acid, D-stereoisomer of an amino acid, non-

15 naturally occurring amino acid, amino acid analogue or a
mimetic of an amino acid. Structural differences between
a binding polypeptide and functional fragment thereof at
the secondary level including, for example, a change in
alpha helix, loop or beta sheet structure can occur so

20 long as the resulting functional fragment retains the
ability to associate with a ligand. A functional
fragment of a binding polypeptide can also have a
structural difference at the tertiary level including,
for example, a change in the relative location of a

25 secondary structure element or change in overall fold of
the binding polypeptide. Structural differences at the
quaternary level can include, for example, a change in
the number of subunits in a binding polypeptide or a
change in the interfaces at which subunits in a binding

30 polypeptide interact so long as the functional fragment
retains the ability to associate with a ligand.

As used herein, the term "complimentarity determining region" or "CDR" is intended to mean a non-contiguous antigen combining site found within the variable region of either a heavy or light chain
5   polypeptides of an immunoglobulin. The term CDR region is well known in the art and has been defined by Kabat et al., U.S. Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983) and by Chothia et al., J. Mol. Biol. 196:901-917 (1987) and
10 additionally by MacCallum et al., J. Mol. Biol. 262:732-745 (1996), which are incorporated herein by reference, and include overlapping or subsets of amino acid residues when compared against each other. Application of any of the above three definitions to
15 refer to a CDR of an antibody, or functional fragment thereof, is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs, as defined by each of the above cited references, are set forth below in Table
20 1 as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid
25 sequence of the antibody.

TABLE 1: CDR Definitions

	Kabat[1]	Chothia[2]	MacCallum[3]
V_H CDR1	31-35	26-32	30-35
V_H CDR2	50-65	52-56	47-58
V_H CDR3	95-102	95-102	93-101
V_L CDR1	24-34	24-34	30-36
V_L CDR2	50-56	50-56	46-55
V_L CDR3	89-97	89-97	89-96

[1] Residue numbering follows the nomenclature of Kabat et al., *supra*
[2] Residue numbering follows the nomenclature of Chothia et al., *supra*
[3] Residue numbering follows the nomenclature of MacCallum et al., *supra*

As used herein, the term "association rate" refers to the time in which binding polypeptide and ligand become bound to form a complex. Use of the term herein is intended to be consistent with the meaning of the term as it is known in the art. The association rate can be correlated with the time dependent appearance of a species composed of binding polypeptide bound to ligand, the time dependent disappearance of free binding polypeptide or the time dependent disappearance of free ligand in a mixture of species including binding polypeptide and ligand. Free binding polypeptide species refers to a binding polypeptide that is competent to bind at least one ligand and free ligand refers to a ligand that is competent to bind at least one binding polypeptide. The scope of the term association rate is intended to include k_{on}. The association rate is known in the art to be proportional to k_{on} and proportional to the product of K_a and k_{off}.

As used herein, the term "associating," when used in reference to a binding polypeptide and ligand, is intended to refer to the process by which a binding polypeptide and ligand contact each other in a manner
5   that results in the species of binding polypeptide bound to ligand. Use of the term associating is intended to be consistent with the meaning of the term as it is known in the art. The process is different from and can be distinguished by those skilled in the art from the
10 reverse process by which the complex of binding polypeptide bound to ligand dissociates to yield free binding polypeptide and free ligand.

As used herein, the term "k_{on}" refers to the association rate constant equating the association rate
15 with the concentration of the free binding polypeptide and free ligand. The term k_{on} is intended to be consistent with the meaning of the term as it is known in the art. Therefore, k_{on} is a quantitative measure of association rate. For example, when binding polypeptide
20 A and ligand B associate to form the bound species AB, the association rate will equal the k_{on} multiplied by the product of the concentration of free binding polypeptide A multiplied by the concentration of free ligand B. A mathematical equation describing this relationship is:
25 association rate = $k_{on}*[A]*[B]$ where [A] is the concentration of polypeptide A and [B] is the concentration of ligand B.

As used herein, the term "K_a" refers to the association constant and is intended to be consistent
30 with the meaning of the term as it is understood in the art. The K_a is a measure of the strength, affinity and

tightness of binding. Specifically K_a is an equilibrium
constant equating the concentrations of free binding
polypeptide, free ligand and binding polypeptide bound to
ligand occurring at equilibrium. The K_a can be used to
5 compare the affinity of different binding polypeptides
for various ligands at equilibrium. For example, a
binding polypeptide with a higher numerical value of K_a
for binding a ligand compared to the K_a for a second
binding polypeptide binding the same ligand is understood
10 in the art to have higher affinity for that ligand. The
K_a relates the association rate constant (k_{on}) and the
dissociation rate constant (k_{off}) according to the
relationship $K_a = k_{on}/k_{off}$. The k_{off} is the mathematical
constant used in the art to quantitate the time for an
15 associated binding polypeptide and ligand to separate.
Accordingly, k_{on} is the product of K_a and k_{off}. The
mathematical inverse of K_a is known in the art as the K_d
or dissociation constant. Therefore, $K_d = 1/K_a = k_{off}/k_{on}$.
Thus, a binding polypeptide with a lower numerical value
20 of K_d for binding a ligand compared to the K_d for a second
binding polypeptide binding the same ligand is understood
in the art to have higher affinity for that ligand.

As used herein, the term "therapeutic potency" is
intended to refer to a predictive measure of efficacy or
25 relative efficacy. If a binding polypeptide has
therapeutic potency it produces a desired therapeutic
effect. Therapeutic potency includes a kinetic property
and is proportional to the association rate for a binding
polypeptide associating with a ligand. As such, the term
30 reflects the effect of expeditious association between a
binding polypeptide and ligand that cures, alleviates,
removes or lessens the symptoms of, or prevents or

reduces the possibility of contracting a pathological condition. A binding polypeptide having an increased k_{on} when associating with a ligand will display more expeditious association with a ligand thereby having improved therapeutic potency compared to a parent polypeptide or other polypeptide having a lower k_{on} when associating with the same ligand.

As used herein, the term "therapeutic control" refers to a molecule to which a binding polypeptide can be compared when determining or identifying therapeutic potency and which is related to a pathological condition to which the binding polypeptide is targeted. A molecule can be related to a pathological condition, for example, by having demonstrated efficacy in treating the pathology, having demonstrated interaction with a ligand associated with a pathological condition, or having properties identified in the art as holding promise for treating a pathology. The scope of the term is intended to include all molecules independent of structural similarity or difference compared to the binding polypeptide so long as both can bind the same ligand. The molecule can be, for example, a naturally occurring molecule, a synthetic molecule, compound or macromolecule.

As used herein the term "changing" when used in reference to a parent polypeptide refers to modifying the structure of the parent polypeptide. Modification of the structure of a parent polypeptide can include, for example, adding a moiety, deleting an amino acid, substituting an amino acid or chemically modifying an amino acid. A moiety that can be substituted includes,

for example, a chemically derivatized amino acid,
D-stereoisomer of an amino acid, non-naturally occurring
amino acid, amino acid analogue or mimetic of an amino
acid. A chemical modification of an amino acid includes,
for example, a covalent change in the bonding structure
of an amino group at the alpha position, lysine,
histidine, arginine, or tryptophan; covalent change in
the bonding structure of a carbonyl at the alpha
position, aspartate or glutamate or covalent change in
the bonding structure of a sulfur at cysteine, cystine or
methionine.

As used herein, the term "measuring," when used in
reference to an association rate, refers to a
determination correlating the appearance of a species
composed of a binding polypeptide bound to ligand with at
least one defined time interval. Therefore, the term
encompasses determination of an amount of time or rate at
which a binding polypeptide binds to a ligand.
Determination of association rate is meaningful when
performed in a non-equilibrium state. Non-equilibrium
states include, for example, pre-equilibrium, which can
occur following mixture of free ligand with free binding
polypeptide and post-equilibrium, which can occur
following altering the concentration of species in an
equilibrated mixture. Post-equilibrium determination of
association rate includes, for example determination of
k_{off} and using the value to calculate k_{on} from K_a or K_d
measured for the binding polypeptide and ligand.

Pre-equilibrium determination of association rate
includes a relative determination, quantitative
determination or time based selection. A relative

determination includes a method involving comparing rates
of association for two binding molecules under similar
conditions such that quantitation of individual rates is
not necessary. A quantitative determination includes a
5   method for determining numerical value for an association
rate or a rate constant such as k_{on}. A time based
selection includes, for example, exploiting a change in a
property of a ligand or binding polypeptide that occurs
when a binding polypeptide associates with ligand so as
10   to select the bound species at a specified time interval.

A determination correlating the appearance of a
species composed of a binding polypeptide bound to ligand
involves a time dependent change, from a first state to a
second state, for any property that changes when the
15   binding polypeptide associates with ligand including, for
example, absorption and emission of heat, absorption and
emission of electromagnetic radiation, refractive index
of surrounding solvent, affinity for a receptor,
molecular weight, density, electric charge, polarity,
20   molecular shape, or molecular size. A property that
changes when a binding polypeptide associates with ligand
can be transient, returning to the first state while the
binding polypeptide is bound to ligand, or can remain in
the second state the entire time that the binding
25   polypeptide and ligand are bound.

As used herein, the term "identifying," when used
in reference to a binding polypeptide with an increased
association rate, refers to recognizing a binding
polypeptide as having an increased association rate. A
30   binding polypeptide having increased association rate can
be recognized prior to being isolated from a population,

after being isolated from a population or the process of
isolating the binding polypeptide from a population can
be a form of recognizing a binding polypeptide with an
increased association rate. A binding polypeptide having

5   increased association rate can be recognized by comparing
the association rate or k_{on} value with an association rate
or k_{on} value for another binding molecule or by selecting
a binding polypeptide based on a more rapid association
rate. As such, recognizing a binding polypeptide with an

10   improved association rate or k_{on} can involve manual
methods or automated methods.

As used herein the term "pathological condition"
refers to a disease or abnormal condition including, for
example, an injury of a mammalian cell or tissue. A

15   pathological condition can be a disease or abnormal
condition that results in unwanted or abnormal cell
growth, viability or proliferation. A pathological
condition characterized by unwanted or abnormal cell
growth includes, for example, cancer or other neoplastic

20   condition, infectious disease or autoimmune disease. For
example, cancer cells proliferate in an unregulated
manner and consequently result in tissue destruction.
Similarly, the proliferation of cells mediating
autoimmune diseases are aberrantly regulated which

25   results in, for example, the continued, proliferation and
activation of immune mechanisms with destruction of the
host's cells and tissue. Specific examples of cancer
include prostate, breast, lung, ovary, uterus, brain and
skin cancer. Specific examples of infectious diseases

30   include DNA or RNA viral diseases, bacterial diseases,
parasitic diseases whereas autoimmune diseases include,

for example, diabetes, rheumatoid arthritis and multiple sclerosis.

The invention provides a binding polypeptide, or functional fragment thereof, having a k_{on} of at least about 9×10^7 $M^{-1}s^{-1}$ for associating with a ligand and
5 having therapeutic potency.

A binding polypeptide having therapeutic potency will demonstrate a therapeutic effect and exhibit expeditious association with a ligand to cure, alleviate, remove or lessen the symptoms of, or prevent or reduce
10 the possibility of contracting a pathological condition. A binding polypeptide of the invention having therapeutic potency is understood to be a high potency binding polypeptide. Therapeutic potency can be identified *in vitro* according to a kinetic property, specifically, the
15 association rate for binding polypeptide associating with a ligand. A binding polypeptide having therapeutic potency can be, for example, a binding polypeptide that prevents or reduces a pathological condition by associating with a ligand and preventing its binding to a
20 receptor that is localized on a cell surface. A binding polypeptide having an increased association rate when associating with a ligand will have improved therapeutic potency compared to a polypeptide, including a binding polypeptide, that has a lower association rate when
25 associating with the same ligand. Therefore, association rate indicates, and correlates with, therapeutic potency and, as such, provides a predictive measure of efficacy or relative efficacy.

A binding polypeptide can also be, for example, attached to a cytotoxic or cytostatic agent so as to deliver the agent to a cell experiencing a pathological condition by associating with a ligand localized on the

5 surface of the cell. A binding polypeptide attached to a cytotoxic or cytostatic agent having an increased association rate when associating with the ligand will have improved therapeutic potency compared to a polypeptide that has a lower association rate when

10 associating with the same ligand.

A binding polypeptide of the invention will be identified according to its ability to selectively associate with a ligand. Selective binding between a binding polypeptide and a ligand can be identified by

15 methods known in the art. Methods of determining selective binding include, for example, equilibrium binding analysis, competition assays, and kinetic assays as described in Segel, Enzyme Kinetics John Wiley and Sons, New York (1975), which is incorporated herein by

20 reference. Thermodynamic constants can be used to identify and compare binding polypeptides and ligands that selectively bind each other and include, for example, dissociation constant or K_d, association constant or K_a and Michaelis constant or K_m.

25 A binding polypeptide that can be used in the methods of the invention includes any polypeptide known to bind a ligand, made to bind a ligand, or known to be capable of binding a ligand. Therefore, a binding polypeptide of the invention can be selected from the

30 group consisting of a receptor, enzyme, hormone, immunoglobulin, antibody, humanized antibody, human

antibody, T-cell receptor, integrin, hormone receptor, lectin, membrane receptor, transmitter receptor, protease, oxidoreductase, kinase, phosphatase, DNA modifying enzyme, transcription factor, GTPase, ATPase,
5 membrane channel, growth factor, insulin, cytokine, neural peptide, extracellular matrix protein and clotting factor, or functional fragments thereof.

A binding polypeptide can be a naturally or non-naturally occurring polypeptide. A naturally occurring
10 binding polypeptide can be obtained, for example, from a native tissue by directly isolating the polypeptide or by isolating the nucleotide encoding the polypeptide and expressing the polypeptide in a recombinant system. One skilled in the art can isolate the nucleotide encoding
15 the polypeptide and express the polypeptide in a recombinant expression system according to methods known in the art as described, for example, in Goeddel, Methods in Enzymology, Vol 185, Academic Press, San Diego (1990); Wu, Methods in Enzymology, Vol 217, Academic Press, San
20 Diego (1993); Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1992), and in Ausebel et al., Current protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (2000), which are incorporated herein by reference.
25 Methods of isolation of a parent polypeptide from recombinant and native tissues are well known in the art and are described, for example, in Scopes, Protein Purification: Principles and Practice, 3rd Ed., Springer-Verlag, New York (1994); Duetscher, Methods in
30 Enzymology, Vol 182, Academic Press, San Diego (1990), and Coligan et al., Current protocols in Protein Science,

John Wiley and Sons, Baltimore, MD (2000), which are incorporated herein by reference.

A naturally occurring binding polypeptide can be, for example, synthesized or produced in a recombinant expression system. For example, a binding polypeptide can be identified from a polypeptide sequence or a sequence of a nucleotide encoding a polypeptide isolated from a natural source or the nucleotide or polypeptide sequence can be obtained from a sequence data base including, for example, GenBank or other databases known in the art. Methods for isolating and sequencing nucleotides and polypeptides are well known in the art and are described, for example, in Sambrook et al., *supra* and in Ausubel et al., *supra*. A binding polypeptide can be expressed in a recombinant system using methods well known in the art including, for example, those described herein below. A binding polypeptide can also be produced by synthetic methods well known in the art, for example, Merrifield solid phase synthesis, t-Boc based synthesis, Fmoc synthesis and variations thereof.

A binding polypeptide of the invention can be non-naturally occurring. A non-naturally occurring polypeptide can be selected, for example, from a randomized population of polypeptides. A randomized population of non-naturally occurring polypeptides can be produced by peptide synthesis methods that are well known in the art including, for example, those described above. Methods of selecting a parent polypeptide from a population of polypeptides will be specific to the parent polypeptide to be selected, and can be achieved using

methods well known by one skilled in the art based on the physical and chemical properties of the polypeptide.

A binding polypeptide of the invention can be a naturally occurring or non-naturally occurring
5 polypeptide that is modified for use in the methods of the invention. A modification to facilitate use of a binding polypeptide in the methods of the invention can include, for example, incorporation of a label for detection of the polypeptide, incorporation of a binding
10 group for capture of a binding polypeptide or modification to increase stability of the polypeptide. A label that can be incorporated includes, for example, a fluorophore, chromophore, paramagnetic spin label, or radionucleotide. A binding group that can be used to
15 capture a polypeptide includes, for example, a biotin, polyhistidine tag (Qiagen; Chatsworth, CA), antibody epitope such as the flag peptide (Sigma; St Louis, MO), glutathione-S-transferase (Amersham Pharmacia; Piscataway, NJ), cellulose binding domain (Novagen;
20 Madison, WI), calmodulin (Stratagene; San Diego, CA), staphylococcus protein A (Pharmacia; Uppsala, Sweden), maltose binding protein (New England BioLabs; Beverley, MA) or strep-tag (Genosys; Woodlands, TX) or minor modifications thereof. A modifications to increase
25 stability can include, for example, incorporation of a cysteine to form a thioether crosslink, removal of a protease recognition sequence, addition of a charged amino acid to promote ionic interactions, or addition of a hydrophobic amino acid to promote hydrophobic
30 interactions. The methods of the invention can accommodate other modifications that can confer additional properties onto the binding polypeptide of the

invention so long as such modifications do not inhibit
binding activity of the binding polypeptide. Examples
include, addition of amino acids, deletion of amino
acids, substitution of amino acids, chemical modification
5 of amino acids and incorporation of non-natural amino
acids.

A binding polypeptide of the invention is intended
to include minor structural modifications that do not
significantly change binding activity. For example,
10 homologs or·isotypes of a binding polypeptide can be
isolated or synthesized that have minor structural
modifications and similar binding activity when compared
to the binding polypeptide and are included in the scope
of a binding polypeptide of the invention. One skilled
15 in the art can identify homologs or isotypes, for
example, by aligning the sequences with an algorithm such
as BLAST (Altschul et al., J. Mol. Biol. 215:403-410
(1990)), WU-BLAST2 (Altschull and Gish, Meth. Enzymol.
266:460-480 (1996)), FASTA (Pearson, Meth. Enzymol.
20 266:227-258 (1996)), or SSEARCH (Pearson, supra) to
identify regions of structural homology. One skilled in
the art can also identify homologues or isotypes using an
algorithm that compares polypeptide structure including,
for example, SCOP, CATH, or FSSP which are reviewed in
25 Hadley and Jones Structure 7:1099-1112 (1999). The
publications cited to reference sequence and structural
alignment algorithms are incorporated herein. Site
directed mutagenesis methods including, for example,
those described herein, can be used to make the
30 appropriate changes to modify homologous polypeptides to
have similar association rate and therapeutic potency as
a binding polypeptide of the invention. Differences

between the homologous binding polypeptides having an insignificant effect on association rate and, therefore, therapeutic potency are considered to be minor modifications. For example, a second antibody from a

5   second species can be modified to have similar association rate when associating with a ligand when compared to a first antibody from a first species that was produced or used in the methods of the invention.

Minor modifications that do not significantly
10   change binding activity include, for example, a change made in a region of a binding polypeptide that does not affect the function of a region of the binding polypeptide that contacts ligand, conservative substitution of one or more amino acids that does not
15   affect interactions between a binding polypeptide and ligand, and substitution of a functionally equivalent amino acid. A change made in the region that does not affect the function of a region of the binding polypeptide that contacts a ligand can include, for
20   example, addition of one or more amino acid, addition of one or more moiety, deletion of one or more amino acid, substitution of one or more amino acid or chemical modification of one or more amino acid. A minor modification can be conservative substitution of an amino
25   acid. Conservative substitutions of encoded amino acids can include, for example, amino acids which belong within the following groups: (1) non-polar amino acids (Gly, Ala, Val, Leu, and Ile); (2) polar neutral amino acids (Cys, Met, Ser, Thr, Asn, and Gln); (3) polar acidic
30   amino acids (Asp and Glu); (4) polar basic amino acids (Lys, Arg and His); and (5) aromatic amino acids (Phe, Trp, Tyr, and His). Other minor modifications are

included so long as the binding polypeptide retains binding activity. The substitution of functionally equivalent amino acids is routine and can be accomplished by methods known to those skilled in the art. Briefly, the substitution of functionally equivalent amino acids can be made by identifying the amino acids which are desired to be changed, incorporating the changes into the encoding nucleic acid and then determining the function of the recombinantly expressed and modified binding polypeptide.

The invention also provides a grafted antibody, or functional fragment thereof, having a k_{on} of at least about 1.3×10^6 M^{-1} s^{-1} to a ligand and having therapeutic potency.

In one embodiment of the invention the binding polypeptide having therapeutic potency or high potency can be a grafted antibody. Grafted antibodies and methods for making grafted antibodies have been described herein previously. Accordingly, an antibody or functional fragment thereof can have human constant regions, or a heavy or light chain framework region at least a part of which is derived from one or more human antibody. A heavy or light chain framework regions used in an antibody or fragment can be derived from a particular antibody or from a consensus sequence of human antibodies. A grafted antibody having therapeutic potency can be produced or identified by the methods of the invention. An antibody or functional fragment thereof of the invention can be an antibody other than vitaxin.

The invention also provides a human antibody, or functional fragment thereof, comprising a k_{on} of at least about 9×10^7 $M^{-1}s^{-1}$ to a ligand and having therapeutic potency. Methods for identifying and producing human antibodies are well known in the art including, for example, those described in Harlow and Lane, *supra.*

An antibody or immunoglobulin of the invention can be a neutralizing antibody or neutralizing immunoglobulin. The term "neutralizing" refers to the ability to reduce the replication of microorganisms or viruses in an organism or in a cell that is cultured. Thus, an antibody or functional fragment thereof having therapeutic potency can have specificity for an antigenic determinant found on a microbe such as a virus, bacteria or fungus. Examples of viruses to which an antibody or fragment thereof can have specificity are respiratory syncytial virus or parainfluenza virus. A neutralizing antibody or neutralizing immunoglobulin the invention including active fragments thereof can be specific for at least one protein expressed by a virus such as RSV or PIV. A protein expressed by the RSV can be the F protein.

The invention provides a method of determining the therapeutic potency of a binding polypeptide. The methods consist of (a) contacting a binding polypeptide with a ligand; (b) measuring association rate for binding between the binding polypeptide and the ligand, and (c) comparing the association rate for the binding polypeptide to an association rate for a therapeutic control, the relative association rate for the binding polypeptide compared to the association rate for the

therapeutic control indicating that the binding polypeptide will exhibit a difference in therapeutic potency correlative with the difference between the association rates. The invention further provides a method where the association rate is indicated by k_{on}. For example, the k_{on} for a binding polypeptide of the invention can be at least about 8×10^6 $M^{-1}s^{-1}$. A binding polypeptide of the invention can also have a k_{on} of at least about 9×10^6 $M^{-1}s^{-1}$, 1×10^7 $M^{-1}s^{-1}$, 2×10^7 $M^{-1}s^{-1}$, 3×10^7 $M^{-1}s^{-1}$, 4×10^7 $M^{-1}s^{-1}$, 5×10^7 $M^{-1}s^{-1}$, 6×10^7 $M^{-1}s^{-1}$, 7×10^7 $M^{-1}s^{-1}$, 8×10^7 $M^{-1}s^{-1}$, 9×10^7 $M^{-1}s^{-1}$, or 1×10^8 $M^{-1}s^{-1}$ or higher. Binding polypeptides having lower k_{on} can also have therapeutic potency. For example, a therapeutically potent polypeptide can have k_{on} less than 8×10^6 $M^{-1}s^{-1}$. Thus, binding polypeptides having k_{on} of 1×10^6 $M^{-1}s^{-1}$ can have therapeutic potency as can polypeptides having k_{on} of 1×10^4 $M^{-1}s^{-1}$. Accordingly, therapeutically potent polypeptides can have k_{on} values of about 5×10^4 $M^{-1}s^{-1}$, 1×10^5 $M^{-1}s^{-1}$, 2.5×10^5 M^{-1} sec^{-1}, 5×10^5 $M^{-1}s^{-1}$ or 7.5×10^5 M^{-1} sec^{-1}.

An association rate can be determined in any non-equilibrium mixture including, for example, one formed by rapidly contacting a binding polypeptide and ligand or by rapidly changing temperature. A non-equilibrium mixture can be a pre-equilibrium mixture. A pre-equilibrium mixture can be formed, for example, by contacting a soluble binding polypeptide and soluble ligand in a condition where the amount of total ligand and total binding polypeptide in the detection chamber are constant. Measurements of association rates in pre-equilibrium mixtures can be made in formats providing rapid mixing of binding polypeptide with ligand and rapid

detection of changing properties of the binding
polypeptide or ligand on a timescale of milliseconds or
faster. Stopped flow and rapid quench flow instruments
such as those described below provide a convenient means
5   to measure non-equilibrium kinetics. The association
rate can also be measured in non-equilibrium mixtures
including, for example, solutions containing insoluble
species of binding polypeptide, ligand or binding
polypeptide bound to ligand, or solutions containing
10 variable concentrations of total ligand or total binding
polypeptide. Measurement of an association rate in a
non-equilibrium mixture can be made in formats providing
attachment of a ligand to a surface and continuous flow
of a solution containing the binding polypeptide over the
15 surface, or vice-versa, combined with rapid detection of
changing properties of the binding polypeptide, ligand or
surface such that measurements are made on a timescale of
milliseconds or faster. Examples of formats providing
non-equilibrium measurement of association rates include
20 surface plasmon resonance instruments and evanescent wave
instruments as described below.

Binding polypeptides and ligands to be contacted
in mixtures for determination of association rate can be
attached to another molecule, ligand or surface so long
25 as they are capable of binding with their ligand or
binding polypeptide partner respectively. Molecules that
can be attached to a binding polypeptide or ligand
include, for example, labels and binding groups such as
those described herein previously for incorporation into
30 binding polypeptide. Attached ligands can include, for
example, an inhibitor that is competitively displaced
when binding occurs between binding polypeptide and

ligand, a second ligand that binds to the binding
polypeptide such that binding can occur between the
binding polypeptide and ligand of interest, or a second
binding polypeptide that binds to ligand such that
5 binding can occur between the binding polypeptide of
interest and the ligand. Attached surfaces can include,
for example, a dextran surface, polymer bead, biological
membrane, or any biosensor surface.

Association rate measurements can be made by
10 detecting the change in a property of the binding
polypeptide or ligand that exists between the bound and
unbound state or by detecting a change in the surrounding
environment when binding polypeptide and ligand
associate. Properties of the binding polypeptide or
15 ligand that can change upon association and that can be
used to measure association rates include, for example,
absorption and emission of heat, absorption and emission
of electromagnetic radiation, affinity for a receptor,
molecular weight, density, mass, electric charge,
20 conductivity, magnetic moment of nuclei, spin state of
electrons, polarity, molecular shape, or molecular size.
Properties of the surrounding environment that can change
when binding polypeptide associates with ligand include,
for example, temperature and refractive index of
25 surrounding solvent.

Formats for measuring association rates in pre-
equilibrium mixtures include, for example, stopped flow
kinetic instruments and rapid quench flow instruments. A
stopped flow instrument can be used to push solutions
30 containing a binding polypeptide and ligand from separate
reservoirs into a mixing chamber just prior to passage

into a detection cell. The instrument can then detect a change in one or more of the above described properties to monitor progress of the binding event. A rapid quench flow instrument can be used to rapidly mix a solution

5 containing a binding polypeptide with a solution containing a ligand followed by quenching the binding reaction after a finite amount of time. A change in one or more of the above described properties can then be detected for quenched mixtures produced by quenching at

10 different times following mixing. Quenching can be performed for example by freezing or addition of a chemical quenching agent so long as the quenching step does not inhibit detection of the property relied upon for measurement of binding rate. Thus, a rapid quench

15 instrument can be useful, for example, in situations where spectroscopic detection is not convenient. A variety of instruments are commercially available from vendors such as KinTek Corp. (State College, PA) and Hi-Tech Scientific (Salisbury, UK).

20   Formats for measuring association rates in non-equilibrium mixtures include, for example, surface plasmon resonance and evanescent wave instruments. Surface plasmon resonance and evanescent wave technology utilize a ligand or binding polypeptide attached to a

25 biosensor surface and a solution containing either the binding polypeptide or ligand respectively that is passed over the biosensor surface. The change in refractive index of the solution that occurs at the surface of a chip when binding polypeptide associates with ligand can

30 be measured in a time dependent fashion. For example, surface plasmon resonance is based on the phenomenon which occurs when surface plasmon waves are excited at a

metal/liquid interface. Light is directed at, and reflected from, the side of the surface not in contact with sample, and SPR causes a reduction in the reflected light intensity at a specific combination of angle and

5 wavelength. Biomolecular binding events cause changes in the refractive index at the surface layer, which are detected as changes in the SPR signal. The binding event can be either binding association or disassociation between a receptor-ligand pair. The changes in

10 refractive index can be measured essentially instantaneously and therefore allows for determination of the individual components of an affinity constant. More specifically, the method enables accurate measurements of association rates (k_{on}) and disassociation rates (k_{off}).

15 Surface plasmon resonance instruments are available in the art including, for example, the BIAcore instrument, IBIS system, SPR-CELLIA system, Spreeta, and Plasmon SPR and evanescent wave technology is available in the Iasys system as described, for example, in Rich and Myszka,

20 Curr. Opin. Biotech. 11:54-61 (2000).

The association rate can be determined by measuring a change in a property of a ligand or binding polypeptide at one or more discreet time intervals during the binding event using, for example, the methods

25 described above. Measurements determined at discreet time intervals during the binding event can be used to determine a quantitative measure of association rate or a relative measure of association rate. Quantitative measures of association rate can include, for example, an

30 association rate value or k_{on} value. Quantitative values of association rate or k_{on} can be determined from a mathematical or graphical analysis of a time dependent

measurement. Such analyses are well known in the art and
include algorithms for fitting data to a sum of
exponential or linear terms or algorithms for computer
simulation to fit data to a binding model as described
5 for example in Johnson, <u>Cur. Opin. Biotech.</u> 9:87-89
(1998), which is incorporated herein by reference.

Association rates can be determined from mixtures
containing insoluble species or variable concentrations
of total ligand or total binding polypeptide using
10 mathematical and graphical analyses such as those
described above if effects of mass transport are
accounted for in the reaction. One skilled in the art can
account for mass transport by comparing association rates
under conditions having similar limitations with respect
15 to mass transport or by adjusting the calculated
association rate according to models available in the art
including, for example those described in Myszka et al.,
<u>Biophys. J.</u> 75:583-594 (1998), which is incorporated
herein by reference.

20 A higher value of either the association rate or
k_{on} is indicative of improved therapeutic potency. Thus,
quantitative determinations provide an advantage by
allowing comparison between an association rate of a
binding polypeptide and a therapeutic control determined
25 by different methods so long as the methods used are
understood by one skilled in the art to yield consistent
results.

A relative measure of association rate can
include, for example, comparison of association rate for
30 two or more binding polypeptides binding to ligand under

similar conditions or comparison of association rate for
a binding polypeptide binding to ligand with a predefined
rate. Comparison of association rate for two or more
binding polypeptides can include a standard of known
5   association rate or a molecule of known therapeutic
effect. A predefined rate used for comparison can be
determined by calibrating the measurement to be relative
to a previously measured rate including, for example, one
available in the scientific literature or in a database.
10 An example of a comparison with a predefined rate is
selection of the species of binding polypeptide bound to
ligand at a discreet time interval defined by the
predefined rate by using a time actuated selection
device.

15   An advantage of the invention is that the methods
can be used with any ligand that mediates or specifically
correlates with a pathological condition. The methods
can also be used with a structurally modified adduct of a
ligand that mediates or specifically correlates with a
20 pathological condition, or a ligand that mimics binding
function of a ligand that mediates or specifically
correlates with a pathological condition. Structural
modifications can facilitate use of a ligand in the
methods of the invention and can include, for example,
25 incorporation of labels for detection of the ligand,
incorporation of binding groups for capture of the ligand
or modifications to increase stability of the ligand.
Labels, binding groups and modifications to increase
stability include, for example, those described herein
30 previously for incorporation into polypeptides. It can
also be advantageous to use a mimic of the ligand to bias
the binding interaction with respect to a subset of

physical interactions that influence its functional association with a binding polypeptide. Physical interactions that allow a ligand and binding polypeptide to associate include, for example, hydrogen bonds, ionic forces, van der Waals interactions or hydrophobic interactions or a combination thereof.

A ligand used with the methods of the invention can be synthesized or isolated from a natural source by a variety of methods known in the art. Synthetic methods for synthesizing a ligand include, for example, organic synthesis, cell free synthesis using extracted cellular components, and chemical synthesis. A ligand that is a polypeptide or nucleic acid can be synthesized, for example, in a recombinant expression system using methods similar to those described below. Additionally, a ligand can be produced in a recombinant organism modified to express one or more enzymes that convert a host intermediate or exogenously supplied intermediate into the ligand. Isolation of a ligand from a natural source can be performed by methods known in the art. For example, a polypeptide or nucleic acid based ligand can be isolated as described herein for a parent polypeptide or binding polypeptide and their encoding nucleic acids. Small molecule ligands can be isolated according to methods known in the art including, for example, extraction, chromatography, crystallization or distillation. Methods of isolating small molecules can be found, for example, in Gordon and Ford, The Chemist's Companion, John Wiley and Sons (1973) and Vogel, Vogel's Textbook of Practical Organic Chemistry, 5th Ed., Addison-Wesley Pub. Co. (1989).

Binding polypeptides having improved therapeutic potency can be determined or identified by comparing an association rate for binding between a binding polypeptide and ligand with an association rate for a

5 therapeutic control binding to the ligand. Since the therapeutic potency of the therapeutic control is correlated with its association rate for associating with a ligand, the therapeutic control provides a means of determining therapeutic potency according to association

10 rates measured *in vitro*.

A therapeutic control can be any molecule so long as the molecule associates with the same ligand as the binding polypeptide to be compared. The therapeutic control of the invention can include, for example, a

15 receptor, enzyme, hormone, immunoglobulin, antibody, humanized antibody, human antibody, T-cell receptor, integrin, hormone receptor, lectin, membrane receptor, transmitter receptor, protease, oxidoreductase, kinase, phosphatase, DNA modifying enzyme, transcription factor,

20 GTPase, ATPase, membrane channel, growth factor, insulin, cytokine, neural peptide, extracellular matrix protein, clotting factor, or functional fragments thereof.

For purposes of comparison, the association rate of a binding polypeptide and ligand can be determined

25 relative to association rate for a therapeutic control and the same ligand. A comparison can also be made according to a quantitative association rate for binding polypeptide and ligand compared to a quantitative association rate for a therapeutic control and ligand.

30 Relative or quantitative association rates can be determined by the methods described above. Determination

of association rates for a binding polypeptide
associating with a ligand can be performed simultaneously
with a binding polypeptide and therapeutic control or at
separate times provided conditions are sufficiently
5 similar in each assay to allow valid comparison. Thus,
association rate determined for a binding polypeptide by
the methods of the invention can be compared to a
previously measured association rate for a therapeutic
control.

10   The invention provides a method of determining the
therapeutic potency of a binding polypeptide. The method
consists of (a) contacting a binding polypeptide with a
ligand; (b) measuring association rate for binding
between the binding polypeptide and the ligand; (c)
15 comparing the association rate for the binding
polypeptide to an association rate for a therapeutic
control, the relative association rate for the binding
polypeptide compared to the association rate for the
therapeutic control indicating that the binding
20 polypeptide will exhibit a difference in therapeutic
potency correlative with the difference between the
association rates, and (d) changing one or more amino
acids in the binding polypeptide and repeating steps (a)
through (c) one or more times. In addition, steps (a)
25 through (d) can be repeated one or more times and stopped
at step (c). Increased association rate correlates with
improved therapeutic potency where increases in
association rate can be at least 4-fold, 5-fold, 6-fold,
7-fold, 8-fold, 9-fold or 10-fold or more.

30   Steps (a) through (c), as recited above, can be
performed according to methods described herein

previously for determining therapeutic potency of a
binding polypeptide by measuring association rate. Step
(d), recited above, provides an advantage in allowing one
skilled in the art to use the methods of the invention to
5 change the therapeutic potency of a binding polypeptide
by changing the binding polypeptide and identifying a
difference in therapeutic potency of the changed binding
polypeptide from an association rate. Therapeutic
potency of a binding polypeptide can be altered by
10 changing the binding polypeptide to have an increased or
decreased association rate when binding a ligand or to
have an increased association rate when binding a new
ligand. A binding polypeptide changed by the methods of
the invention to have improved therapeutic potency by
15 binding to a new ligand can have substantially unaltered
association rate for the original ligand or can have an
increase or decrease in association rate for the original
ligand. Binding of a new ligand to a changed binding
polypeptide can be competitive with binding of the
20 original ligand, non-competitive with binding of the
original ligand, or allosteric with binding of the
original ligand. Competitive, non competitive and
allosteric binding of two ligands to a binding
polypeptide can be recognized by methods available in the
25 art as described in Segel, *supra*.

Amino acids to be changed in a polypeptide in
order to change therapeutic potency can be incorporated
randomly or incorporated based on knowledge of the
interactions between the binding polypeptide and ligand.
30 Random incorporation includes, for example, incorporating
each of the twenty naturally occurring amino acid
residues, or a subset thereof, at one or more defined

position or incorporating each of the twenty naturally
occurring amino acid residues, or a subset thereof, at
random positions in the polypeptide or portion thereof.
For example, a portion of a polypeptide can be randomly
5 changed to incorporate all 20 natural amino acids or a
subset thereof. As an example of changing random sites
in a polypeptide, a polypeptide can be randomly mutated
along its entire sequence by incorporating all 20 natural
amino acids or a subset thereof.

10   Knowledge of interactions between a binding
polypeptide and ligand can be used to guide site directed
changes, to bias random changes, or to produce biased
changes. For example, if residues of the original
binding polypeptide are known to interact with a ligand
15 these residues can be altered to accommodate or invoke
interactions with a second ligand at the same site.
Knowledge of the interactions between binding polypeptide
and ligand can include, for example, identification of
residues in the binding polypeptide that interact with
20 the ligand, identification of residues that affect the
structure or function of the binding polypeptide binding
site or identification of residues that are proximal to
the binding polypeptide ligand binding site. Such
interactions can be derived from information on the
25 structure and function of the binding polypeptide, ligand
or binding polypeptide bound to ligand.

      Structure and function information can be used to
identify interactions between a binding polypeptide and
ligand. For example, interactions can be identified from
30 a structural model, amino acid sequence, functional
binding data, or identification of sites or regions

labeled with reagents that selectively modify amino acids
of a binding polypeptide. Structural models of a binding
polypeptide can be derived from, for example, X-ray
crystallography, nuclear magnetic resonance spectroscopy,
5 electron microscopy, atomic force microscopy, X-ray
scattering or neutron scattering. A structural model can
include structure of a binding polypeptide, structure of
a ligand or structures of both a binding polypeptide and
bound ligand. Molecular modeling can be used in
10 conjunction with a structural model to identify potential
interactions between a binding polypeptide and ligand.

The amino acid sequence of a binding polypeptide
or ligand can be used, for example, to determine binding
residues according to homology with other binding
15 polypeptides and ligands. For example, amino acids to be
changed in a first binding polypeptide can be chosen
based on homology to amino acids known to interact with a
ligand in a second polypeptide. Again molecular modeling
can be used in conjunction with a homology search to
20 model a putative structure for the binding polypeptide or
ligand thereby allowing identification of potential
interacting amino acids.

Functional binding studies with modified binding
polypeptides can be useful in identifying regions to
25 change in the methods of the invention. For example, a
change in binding activity that correlates with a change
in an amino acid of a binding polypeptide can indicate
that the changed amino acid position potentially
interacts with a ligand.

The size of a population of polypeptides produced
from a randomly changed polypeptide can be minimized by
introducing a bias into random mutagenesis methods. A
bias can be introduced with respect to the particular
5   amino acids to be incorporated, with respect to the amino
acid sites at which a polypeptide is changed, or with
respect to both the particular amino acid to be
incorporated and the site of incorporation.

A bias can also be introduced into the
10   randomization at a specified position based on
conservative substitutions. Conservative substitutions
of amino acids include, for example, (1) non-polar amino
acids (Gly, Ala, Val, Leu and Ile); (2) polar neutral
amino acids (Cys, Met, Ser, Thr, Asn and Gln); (3) polar
15   acidic amino acids (Asp and Glu); (4) polar basic amino
acids (Lys, Arg and His); and (5) aromatic amino acids
(Phe, Tyr, Trp and His). Additionally, conservative
substitutions of amino acids include, for example,
substitutions based on the frequencies of amino acid
20   changes between corresponding proteins of homologous
organisms as described, for example, in <u>Principles of
Protein Structure</u>, Schulz and Schirmer, eds., Springer
Verlag, New York (1979) which is incorporated herein by
reference.

25   A subset of residues for randomization within a
polypeptide can be chosen based on properties of the
polypeptide. For example, biased mutagenesis of
proteases, protease inhibitors, immunoglobulins, DNA
binding polypeptides and RNA binding polypeptides is
30   described in <u>Methods in Enzymology</u> 267:52-68 (1996),
biased mutagenesis of streptavidin is described in Voss

and Skerra, Prot. Eng. 10:975-982 (1997), biased
mutagenesis of binding polypeptides having a lipocalin
fold is described in Beste et al. Proc Natl. Acad. Sci.
USA 96:1898-1903 (1999), biased mutagenesis of growth
5 hormones is described in Ballinger et al., J. Biol. Chem.
273:11675-11684 (1998) and biased mutagenesis of an
antibody is described in Wu et al., Proc. Natl. Acad.
Sci. USA 95:6037-6042 (1998).

Random mutagenesis and biased mutagenesis methods
10 can produce changes at one or more selected positions
without altering the remaining amino acid positions
within a region. For example, a population of single
position changes can contain varied amino acid residues
at each position, incorporated either randomly or with a
15 biased frequency, while leaving the remaining positions
unchanged. For the specific example of a ten residue
region, a population can contain species having the
first, second and third, continued through the tenth
residue, independently randomized or represented by a
20 biased frequency of incorporated amino acid residues
while keeping the remaining positions unchanged. For the
specific example described above, these non-varied
positions would correspond to positions 2-10; 1,3-10;
1,2,4-10, continued through positions 1-9, respectively.
25 Therefore, the resultant population will contain species
that represent all single position changes.

Similarly, double, triple quadruple or more amino
acid position changes can be generated within a region of
a polypeptide without altering the remaining amino acid
30 positions. For example, a population of double position
changes will contain at each set of two positions the

varied amino acid residues while leaving the remaining
positions as unchanged residues. The sets will
correspond to, for example, positions 1 and 2, 1 and 3, 1
and 4, and continued pairwise through the region until

5   the last set corresponds to the first and last positions
of the region. The population will also contain sets
corresponding to positions 2 and 3, 2 and 4, 2 and 5,
through the set corresponding to the second and last
position of the region. Similarly, the population will

10 contain sets of double position changes corresponding to
all pairs of position changes beginning with position
three of the region. Similar pairs of position changes
are made with the remaining sets of amino acid positions.
Therefore, the population will contain species that

15 represent all pairwise combinations of amino acid
position changes. In a similar fashion, populations
corresponding to sets of changes representing all triple
and quadruplet changes along a region can similarly be
targeted using the methods of the invention.

20   Because the methods of the invention can employ
the production and screening of diverse populations of
polypeptides, effects on association rate, such as the
neutralization or augmentation of inherently detrimental
changes and the neutralization or augmentation of

25 beneficial amino acid changes, can occur due to the
combined interactions of two or more amino acid changes
within a single polypeptide. No prior information is
required to assess which amino acid positions or changes
can be inherently beneficial or detrimental, or which

30 positions or changes can be further augmented by second
site changes. Instead, by selecting amino acid positions
or subsets thereof and generating a diverse population

containing amino acid variants at these positions,
combinations of beneficial changes occurring at the
selected positions will be identified by screening for
increased or optimized association rate. Such beneficial
5 combinations will include the unveiling of inherently
beneficial residues and neutralization of inherently
detrimental residues.

Methods for efficient synthesis and expression of
populations of changed polypeptides synthesized using
10 oligonucleotide-directed mutagenesis can be performed,
for example, as previously described in Wu et al. *supra;*
Wu et al., J. Mol. Biol., 294:151-162 (1999) and Kunkel,
Proc. Natl. Acad. Sci. USA, 82:488-492 (1985) which are
incorporated herein by reference.
15 Oligonucleotide-directed mutagenesis is a well known and
efficient procedure for systematically introducing
mutations, independent of their phenotype and is,
therefore, suited for directed evolution approaches to
protein engineering. The methodology is flexible,
20 permitting precise mutations to be introduced without the
use of restriction enzymes, and is relatively
inexpensive. Briefly, to perform oligonucleotide
directed mutagenesis, a population of oligonucleotides
encoding the desired mutation(s) is hybridized to
25 single-stranded uracil-containing template of the wild
type sequence, double-stranded circular DNA is generated
by a polymerase and a ligase, and the mutant DNA is
efficiently recovered following transformation of a *dut⁺*
ung⁺ bacterial strain which can not replicate the uracil
30 containing wild-type template.

Populations of changed polypeptides can also be generated using gene shuffling. Gene shuffling or DNA shuffling is a method for directed evolution that generates diversity by recombination as described, for example, in Stemmer, _Proc. Natl. Acad. Sci. USA_ 91:10747-10751 (1994); Stemmer, _Nature_ 370:389-391 (1994); Crameri et al., _Nature_ 391:288-291 (1998); Stemmer et al., U.S. Patent No. 5,830,721, which are incorporated herein by reference. Gene shuffling or DNA shuffling is a method using _in vitro_ homologous recombination of pools of selected mutant genes. For example, a pool of point mutants of a particular gene can be used. The genes are randomly fragmented, for example, using DNase, and reassembled by PCR. If desired, DNA shuffling can be carried out using homologous genes from different organisms to generate diversity (Crameri et al., _supra_, 1998). The fragmentation and reassembly can be carried out, for example, in multiple rounds, if desired. The resulting reassembled genes are a population of variants that can be used in the invention.

Simultaneous incorporation of all of the encoding nucleic acids and all of the selected amino acid position changes can be accomplished by a variety of methods known to those skilled in the art, including for example, recombinant and chemical synthesis. Simultaneous incorporation can be accomplished by, for example, chemically synthesizing the nucleotide sequence for the region and incorporating at the positions selected for harboring variable amino acid residues a plurality of corresponding amino acid codons.

One method well known in the art for rapidly and efficiently producing a large number of alterations in a known amino acid sequence or for generating a diverse population of variable or random sequences is known as

5   codon-based synthesis or mutagenesis. This method is the subject matter of U.S. Patent Nos. 5,264,563 and 5,523,388 and is also described in Glaser et al. J. Immunology 149:3903 (1992), all of which are incorporated herein by reference. Briefly, coupling reactions for the

10 randomization of, for example, all twenty codons which specify the amino acids of the genetic code are performed in separate reaction vessels and randomization for a particular codon position occurs by mixing the products of each of the reaction vessels. Following mixing, the

15 randomized reaction products corresponding to codons encoding an equal mixture of all twenty amino acids are then divided into separate reaction vessels for the synthesis of each randomized codon at the next position. For the synthesis of equal frequencies of all twenty

20 amino acids, up to two codons can be synthesized in each reaction vessel.

Variations to this synthesis method also exist and include, for example, the synthesis of predetermined codons at desired positions and the biased synthesis of a

25 predetermined sequence at one or more codon positions. Biased synthesis involves the use of two reaction vessels where the predetermined or parent codon is synthesized in one vessel and the random codon sequence is synthesized in the second vessel. The second vessel can be divided

30 into multiple reaction vessels such as that described above for the synthesis of codons specifying totally random amino acids at a particular position.

Alternatively, a population of degenerate codons can be synthesized in the second reaction vessel such as through the coupling of NNG/T nucleotides where N is a mixture of all four nucleotides. Following synthesis of the predetermined and random codons, the reaction products in each of the two reaction vessels are mixed and then redivided into an additional two vessels for synthesis at the next codon position.

A modification to the above-described codon-based synthesis for producing a diverse number of changed sequences can similarly be employed for the production of changed polypeptide populations described herein. This modification is based on the two vessel method described above which biases synthesis toward the parent sequence and allows the user to separate the variants into populations containing a specified number of codon positions that have random codon changes.

Briefly, this synthesis is performed by continuing to divide the reaction vessels after the synthesis of each codon position into two new vessels. After the division, the reaction products from each consecutive pair of reaction vessels, starting with the second vessel, is mixed. This mixing brings together the reaction products having the same number of codon positions with random changes. Synthesis proceeds by then dividing the products of the first and last vessel and the newly mixed products from each consecutive pair of reaction vessels and redividing into two new vessels. In one of the new vessels, the parent codon is synthesized and in the second vessel, the random codon is synthesized. For example, synthesis at the first codon

position entails synthesis of the parent codon in one
reaction vessel and synthesis of a random codon in the
second reaction vessel. For synthesis at the second
codon position, each of the first two reaction vessels is
5   divided into two vessels yielding two pairs of vessels.
For each pair, a parent codon is synthesized in one of
the vessels and a random codon is synthesized in the
second vessel. When arranged linearly, the reaction
products in the second and third vessels are mixed to
10 bring together those products having random codon
sequences at single codon positions. This mixing also
reduces the product populations to three, which are the
starting populations for the next round of synthesis.
Similarly, for the third, fourth and each remaining
15 position, each reaction product population for the
preceding position are divided and a parent and random
codon synthesized.

Following the above modification of codon-based
synthesis, populations containing random codon changes at
20 one, two, three and four positions as well as others can
be conveniently separated out and used based on the need
of the individual. Moreover, this synthesis scheme also
allows enrichment of the populations for the randomized
sequences over the parent sequence since the vessel
25 containing only the parent sequence synthesis is
similarly separated out from the random codon synthesis.

Other methods well known in the art for producing
a large number of alterations in a known amino acid
sequence or for generating a diverse population of
30 variable or random sequences include, for example,
degenerate or partially degenerate oligonucleotide

synthesis. Codons specifying equal mixtures of all four nucleotide monomers, represented as NNN, results in degenerate synthesis. Whereas partially degenerate synthesis can be accomplished using, for example, the

5 NNG/T codon described previously. Other methods well known in the art can alternatively be used such as the use of statistically predetermined, or variegated, codon synthesis which is the subject matter of U.S. Patent Nos. 5,223,409 and 5,403,484, which are incorporated herein by

10 reference.

Once the populations of changed polypeptides encoding nucleic acids have been constructed as described above, they can be expressed to generate a population of changed polypeptides that can be screened for association

15 rate. For example, the nucleic acids encoding the changed polypeptides can be cloned into an appropriate vector for propagation, manipulation and expression. Such vectors are known or can be constructed by those skilled in the art and should contain all expression

20 elements sufficient for the transcription, translation, regulation, and if desired, sorting and secretion of the altered polypeptide or polypeptides. The vectors also can be for use in either procaryotic or eukaryotic host systems so long as the expression and regulatory elements

25 are of compatible origin. The expression vectors can additionally included regulatory elements for inducible or cell type-specific expression. One skilled in the art will know which host systems are compatible with a particular vector and which regulatory or functional

30 elements are sufficient to achieve expression of a polypeptide in soluble, secreted or cell surface forms.

Suitable expression vectors are well-known in the
art and include vectors capable of expressing nucleic
acid operatively linked to a regulatory sequence or
element such as a promoter region or enhancer region that
5   is capable of regulating expression of such nucleic acid.
Promoters or enhancers, depending upon the nature of the
regulation, can be constitutive or inducible. The
regulatory sequences or regulatory elements are
operatively linked to a nucleic acid of the invention or
10 population of changed nucleic acids as described above in
an appropriate orientation to allow transcription of the
nucleic acid.

Appropriate expression vectors include those that
are replicable in eukaryotic cells and/or prokaryotic
15 cells and those that remain episomal or those which
integrate into the host cell genome. Suitable vectors
for expression in prokaryotic or eukaryotic cells are
well known to those skilled in the art as described, for
example, in Ausubel et al., *supra*. Vectors useful for
20 expression in eukaryotic cells can include, for example,
regulatory elements including the SV40 early promoter,
the cytomegalovirus (CMV) promoter, the mouse mammary
tumor virus (MMTV) steroid-inducible promoter, Moloney
murine leukemia virus (MMLV) promoter, and the like. A
25 vector useful in the methods of the invention can
include, for example, viral vectors such as a
bacteriophage, a baculovirus or a retrovirus; cosmids or
plasmids; and, particularly for cloning large nucleic
acid molecules, bacterial artificial chromosome vectors
30 (BACs) and yeast artificial chromosome vectors (YACs).
Such vectors are commercially available, and their uses
are well known in the art. One skilled in the art will

know or can readily determine an appropriate promoter for expression in a particular host cell.

Appropriate host cells, include for example, bacteria and corresponding bacteriophage expression
5 systems, yeast, avian, insect and mammalian cells and compatible expression systems known in the art corresponding to each host species. Methods for recombinant expression of populations of progeny polypeptides or progeny polypeptides within such
10 populations in various host systems are well known in the art and are described, for example, in Sambrook et al., *supra* and in Ansubel et al., *supra*. The choice of a particular vector and host system for expression and screening of progeny polypeptides will be known by those
15 skilled in the art and will depend on the preference of the user. Expression of diverse populations of hetereomeric receptors in either soluble or cell surface form using filamentous bacteriophage vector/host systems is well known in the art and is the subject matter of
20 U.S. Patent No. 5,871,974 which are incorporated herein by reference.

The recombinant cells are generated by introducing into a host cell a vector or population of vectors containing a nucleic acid molecule encoding a binding
25 polypeptide. The recombinant cells are transducted, transfected or otherwise genetically modified by any of a variety of methods known in the art to incorporate exogenous nucleic acids into a cell or its genome. Exemplary host cells that can be used to express a
30 binding polypeptide include mammalian primary cells; established mammalian cell lines, such as COS, CHO, HeLa,

NIH3T3, HEK 293 and PC12 cells; amphibian cells, such as
Xenopus embryos and oocytes; and other vertebrate cells.
Exemplary host cells also include insect cells such as
Drosophila, yeast cells such as *Saccharomyces cerevisiae*,
5   *Saccharomyces pombe*, or *Pichia pastoris*, and prokaryotic
cells such as *Escherichia coli*.

In one embodiment, a nucleic acids encoding a
polypeptide can be delivered into mammalian cells, either
in vivo or *in vitro* using suitable vectors well-known in
10 the art. Suitable vectors for delivering a nucleic acid
encoding a polypeptide to a mammalian cell, include viral
vectors such as retroviral vectors, adenovirus, adeno-
associated virus, lentivirus, herpesvirus, as well as
non-viral vectors such as plasmid vectors.

15   Viral based systems provide the advantage of being
able to introduce relatively high levels of the
heterologous nucleic acid into a variety of cells.
Suitable viral vectors for introducing a nucleic acid
encoding a polypeptide into mammalian cells are well
20 known in the art. These viral vectors include, for
example, Herpes simplex virus vectors (Geller et al.,
Science, 241:1667-1669 (1988)); vaccinia virus vectors
(Piccini et al., Meth. Enzymology, 153:545-563 (1987));
cytomegalovirus vectors (Mocarski et al., in Viral
25 Vectors, Y. Gluzman and S.H. Hughes, Eds., Cold Spring
Harbor Laboratory, Cold Spring Harbor, N.Y., 1988, pp.
78-84)); Moloney murine leukemia virus vectors (Danos et
al., Proc. Natl. Acad. Sci. USA, 85:6460-6464 (1988);
Blaese et al., Science, 270:475-479 (1995); Onodera et
30 al., J. Virol., 72:1769-1774 (1998)); adenovirus vectors

(Berkner, Biotechniques, 6:616-626 (1988); Cotten et al.,
Proc. Natl. Acad. Sci. USA, 89:6094-6098 (1992); Graham
et al., Meth. Mol. Biol., 7:109-127 (1991); Li et al.,
Human Gene Therapy, 4:403-409 (1993); Zabner et al.,

5 Nature Genetics, 6:75-83 (1994)); adeno-associated virus
vectors (Goldman et al., Human Gene Therapy, 10:2261-2268
(1997); Greelish et al., Nature Med., 5:439-443 (1999);
Wang et al., Proc. Natl. Acad. Sci. USA, 96:3906-3910
(1999); Snyder et al., Nature Med., 5:64-70 (1999);

10 Herzog et al., Nature Med., 5:56-63 (1999)); retrovirus
vectors (Donahue et al., Nature Med., 4:181-186 (1998);
Shackleford et al., Proc. Natl. Acad. Sci. USA,
85:9655-9659 (1988); U.S. Patent Nos. 4,405,712,
4,650,764 and 5,252,479, and WIPO publications WO

15 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO
92/14829; and lentivirus vectors (Kafri et al., Nature
Genetics, 17:314-317 (1997)). The above publications
describing vectors or their use are incorporated herein
by reference.

20   In addition to mutagenesis methods described
above, a polypeptide can be changed by chemical
modifications. Chemical modifications can be made to
change the binding properties of a polypeptide, to
benefit measurement of association rates or to benefit

25 identification of a binding polypeptide. A chemical
modification of an amino acid includes, for example,
modification of amino groups by amidination,
guanidination, reductive methylation, carbamylation,
acetylation, trinitrobenzoylation, succinylation or

30 formylation; modification of arginine by butanedione
reaction, phenylglyoxal reaction, or nitromalondialdehyde
reaction; modification of carbonyls by esterification or

carbodiimide coupling; sulfenylation of tryptophan;
modification of tyrosine by nitration or iodination;
modification of sulfhydrils by reduction, oxidation,
carboxymethylation, carboxyerthylation, aminoethylation,
5 methylation, sulphonation, addition of thiols, or
cyanylation. One skilled in the art can chemically
modify a parent polypeptide by methods described in Means
and Feeney, Chemical Modification of Proteins Holden-Day
Inc., San Francisco (1971) and Glazer et al., Chemical
10 Modification of Proteins: Selected methods and analytical
procedures Elsevier Biomedical Press, New York (1975)
which are incorporated herein by reference.

    Changing the structure of a binding polypeptide by
15 the methods described herein provides a means to alter
therapeutic potency by increasing or decreasing the
association rate or by increasing the association rate
for a new ligand. Therefore, binding polypeptides having
increased or decreased therapeutic potency can be
20 identified according to the needs of the practitioner.
The methods of the invention provide for production of a
population of progeny polypeptides that has sufficient
size and diversity to yield a likely probability of
obtaining a binding polypeptide having desired changes in
25 therapeutic potency, whether it be an increases or
decrease. As described previously, the size and
diversity of the population can be adjusted according to
the chosen method of mutagenesis. For example, if random
mutagenesis methods are to be employed then a large
30 population of high diversity can be produced. The size
or diversity of the population can be reduced by using
biased mutagenesis, focused mutagenesis or site directed
mutagenesis. One skilled in the art will be able to

determine the size and diversity of the population of
progeny polypeptides based on the properties of the
particular polypeptide to be changed and which method is
to be used for changing the polypeptide.

5   The methods of the invention provide for
repetition of steps to further optimize the therapeutic
potency of a binding polypeptide. The therapeutic
potency of a binding polypeptide can be optimized by
isolating a binding polypeptide having altered
10 therapeutic potency and repeating the steps of the method
described herein. Specifically, the therapeutic potency
of the isolated binding polypeptide having altered
therapeutic potency can be determined by changing one or
more amino acid, contacting the isolated binding
15 polypeptide having altered therapeutic potency with a
ligand, measuring association rate for binding between
the isolated binding polypeptide having altered
therapeutic potency and the ligand, and comparing the
association rate for the binding polypeptide to an
20 association rate for a therapeutic control. The steps
can be repeated once, twice, or many times until a
desired therapeutic potency is obtained.

      An example of a binding polypeptide that can be
made and used with the methods of the invention is an
25 antibody, or functional fragment thereof. For example,
often grafted antibodies are observed to have reduced
affinity when compared to the donor antibody from which
the CDRs were derived. The methods of the invention can
be used to improve the association rate for a grafted
30 antibody binding to a ligand and, therefore, therapeutic
potency of the grafted antibody. The grafted antibody

binding site can be identified by any or all of the criteria specified previously and in the examples and the methods of the invention described previously with respect to binding polypeptides can be utilized. A
5 grafted antibody can have at least 1, 2, 3, 4, 5 or 6 CDRs from a therapeutically potent antibody or other functional antibody. A CDR of an antibody or fragment thereof can be selected from a light chain CDR such as L1, L2 or L3 or heavy chain CDR such as H1, H2 and H3.

10   The invention further provides a method to determine therapeutic potency of a binding polypeptide where the difference between the k_{on} for a binding polypeptide and the k_{on} for a therapeutic control is independent of an effect of a difference between K_a for
15 the binding polypeptide and K_a for the therapeutic control. Also provided is a method where the difference between the k_{on} for the binding polypeptide and the k_{on} for the therapeutic control can be an increase and K_a for the binding polypeptide can be a similar value to K_a for the
20 therapeutic control. Similarly, a method is provided where the difference between the k_{on} for the binding polypeptide and the k_{on} for the therapeutic control can be an increase and K_a for the binding polypeptide can be a lower value than K_a for the therapeutic control.

25   An advantage of the invention is that a binding polypeptide having improved therapeutic potency can be distinguished from a binding polypeptide that has an increased K_a for a ligand but not improved therapeutic potency. Methods for identifying a therapeutic binding
30 polypeptide based on K_a rely on an equilibrium measurement which, absent time dependent measurements

made in a non-equilibrium condition, are inaccurate for identifying a binding polypeptide having increased association rate and therefore improved therapeutic potency. According to the relationship $K_a = k_{on}/k_{off}$, an increased K_a for association of a binding polypeptide and ligand can be due to changes in k_{on} or k_{off}. For example, a binding polypeptide having improved therapeutic potency can have a reduced K_a if a reduction in k_{off} occurs that over compensates for an increase in k_{on}. Thus, changes in K_a, being influenced by changes in k_{off}, do not unambiguously correlate with changes in therapeutic potency since binding polypeptides having improved therapeutic potency can display either reduced or increased K_a.

A binding polypeptide having therapeutic potency such as an antibody or functional fragment thereof can have a K_a of at least about 1×10^9 M^{-1}, 1×10^{10} M^{-1} or 1×10^{11} M^{-1}. A binding polypeptide of the invention such as an antibody or functional fragment thereof can be evaluated by other known measures such as EC_{50}. A binding polypeptide can have an EC_{50} of less than about 6.0 nM, 3.0 nM, or 1.0 nM.

The invention provides a method of determining therapeutic potency of a binding polypeptide. The method consists of (a) contacting two or more binding polypeptides with a ligand; (b) measuring k_{on} for binding between the two or more binding polypeptides and the ligand, and (c) identifying a binding polypeptide exhibiting a high k_{on}, the k_{on} value correlating with the therapeutic potency of the identified binding polypeptide.

The invention further provides a method of determining therapeutic potency of a binding polypeptide where the method consists of (a) contacting two or more binding polypeptides of a population with a ligand; (b) measuring association rates for the two or more binding polypeptides binding to the ligand; (c) comparing the association rates for the two or more binding polypeptides binding to the ligand, and (d) identifying a binding polypeptide exhibiting a higher association rate for binding to said ligand than one or more other binding polypeptides of the population, said higher association rate correlating with the therapeutic potency of said identified binding polypeptide. The association rate identified by the method can be indicated by k_{on}. The k_{on} of a binding polypeptide exhibiting a higher association rate for a ligand can be at least about 1.5×10^6 $M^{-1}s^{-1}$. A binding polypeptide exhibiting a higher association rate for a ligand can also have a k_{on} of at least about 2×10^6 $M^{-1}s^{-1}$, 4×10^6 $M^{-1}s^{-1}$, 6×10^6 $M^{-1}s^{-1}$, 8×10^6 $M^{-1}s^{-1}$, 1×10^7 $M^{-1}s^{-1}$, 2×10^7 $M^{-1}s^{-1}$, 4×10^7 $M^{-1}s^{-1}$, 6×10^7 $M^{-1}s^{-1}$, 8×10^7 $M^{-1}s^{-1}$, or 1×10^8 $M^{-1}s^{-1}$ or higher. Preferably, a high k_{on} is larger than k_{on} for a therapeutic control.

The step of contacting two or more binding polypeptides of a population with a ligand can be performed with binding polypeptides isolated from the population prior to being contacted with the ligand or a mixture containing two or more binding polypeptides from the population. The step of measuring association rates for a binding polypeptide isolated from the population can be performed according to essentially any of the methods described herein previously. Measuring association rates for binding polypeptides in a mixture

containing two or more binding polypeptides can be performed by relative methods including, for example, selection of a binding polypeptide bound to ligand at a discreet time interval by using a time actuated

5   collection device.

Comparing the association rates for two or more binding polypeptides isolated from a population can be achieved essentially as described previously. Comparing the association rates for two or more binding

10 polypeptides in the same mixture can be achieved by selection methods, for example, using a time actuated device as described above. Such methods of comparison can be made with a population of binding polypeptides containing one or more binding polypeptide that are

15 standards of known association rate or therapeutic potency. Additionally a population containing binding polypeptides of unknown association rate can be measured such that one or more binding polypeptides is identified as having increased association rate and improved

20 therapeutic potency compared to the average for the population.

A population of polypeptides used in the methods of the invention can include 2, 10, 100, 1×10^3, 1×10^4, 1×10^5, 1×10^6, 1×10^7, 1×10^8, 1×10^9, or 1×10^{10} or

25 more different binding polypeptides. As described previously one skilled in the art will be able to determine the size and diversity of the population of binding polypeptides based on the properties of the particular polypeptide to be changed and which method is

30 used to change the polypeptide. One skilled in the art can also alter the number of binding polypeptides to be

measured from a population such that a sub-population can be measured. The number of polypeptides to be measured can be based on factors such as the diversity of the population, the magnitude of change desired in the

5 therapeutic potency, or the degree of bias incorporated during mutagenesis. Accordingly, association rates can be measured for 2, 10, 100, 1×10^3, 1×10^4, 1×10^5, 1×10^6, 1×10^7, 1×10^8, 1×10^9, or 1×10^{10} or more different binding polypeptides from a population.

10 The invention provides a method for producing one or more binding polypeptides with improved therapeutic potency. The method consists of (a) changing one or more amino acids in a parent polypeptide to produce one or more different progeny polypeptides; (b) measuring the

15 association rate for the one or more different progeny polypeptides associating with a ligand, and (c) identifying a binding polypeptide from one or more progeny polypeptides having at least a 4-fold increase in association rate to a ligand compared to the parent

20 polypeptide, the increased association rate resulting in improved therapeutic potency toward a pathological condition. Further provided is a method where the fold increase in association rate is indicated by an increase in k_{on}. Therefore, k_{on} can increase by 4-fold, 5-fold, 6-

25 fold, 7-fold, 8-fold, 9-fold, or 10-fold or more in the methods of the invention. The increased k_{on} can be at least about 3×10^5 $M^{-1}s^{-1}$. The increased k_{on} can also be at least about 5×10^5 $M^{-1}s^{-1}$, 7×10^5 $M^{-1}s^{-1}$, 9×10^5 $M^{-1}s^{-1}$, 1×10^6 $M^{-1}s^{-1}$, 3×10^6 $M^{-1}s^{-1}$, 5×10^6 $M^{-1}s^{-1}$, 7×10^6 $M^{-1}s^{-1}$, 9

30 $\times 10^6$ $M^{-1}s^{-1}$ or 1×10^7 $M^{-1}s^{-1}$ or more. Furthermore, the increase in k_{on} resulting in improved therapeutic potency can be independent of an effect of a change in K_a for the

binding polypeptide. The binding polypeptide having an increase in k_{on} can have a K_a value similar to K_a for its parent polypeptide or a K_a value lower than K_a for its parent polypeptide.

5   A polypeptide changed by the methods of the invention can be a parent polypeptide. A parent polypeptide is one example of a peptide described herein and therefore can have any of the properties thereof and be made and used according to the description provided
10   herein. For example, one or more amino acids in a parent polypeptide can be changed according to the previously described methods to produce one or more different progeny polypeptides. A progeny polypeptide is one example of the changed polypeptides described herein and
15   can therefore be made and used according to the previous descriptions herein. Accordingly, the step of measuring an association rate for one or more different progeny polypeptides associating with a ligand, can be performed as described herein previously. In addition, the step of
20   identifying a binding polypeptide from one or more progeny polypeptides having at least a 4-fold increase in association rate when binding to a ligand compared to its parent polypeptide can be performed according to the methods described previously herein for determining
25   association rates and therapeutic potency.

     The step of identifying a binding polypeptide from one or more progeny polypeptides having at least a 4-fold increase in association rate to a ligand compared
30   to the parent polypeptide can be performed to identify a binding polypeptide from one or more progeny polypeptides

having at least a 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold or greater increase in association rate resulting in improved therapeutic potency toward a pathological condition. Binding polypeptides having a
5 larger fold increase in association rate will have an increased therapeutic potency. Additionally the increased k_{on} can be at least about 1×10^8 $M^{-1}s^{-1}$, 1.5×10^8 $M^{-1}s^{-1}$, 2×10^8 $M^{-1}s^{-1}$, 2.5×10^8 $M^{-1}s^{-1}$, 3×10^8 $M^{-1}s^{-1}$, 4×10^8 $M^{-1}s^{-1}$, 5×10^8 $M^{-1}s^{-1}$, or 1×10^9 $M^{-1}s^{-1}$ or more.

10   Therefore, the invention further provides a method for producing a binding polypeptide with improved therapeutic potency. The method consists of (a) changing one or more amino acids in a parent polypeptide to produce one or more different progeny polypeptides; (b)
15 measuring the association rate for the one or more different progeny polypeptides associating with a ligand, and (c) identifying a binding polypeptide from the one or more different progeny polypeptides having a k_{on} of at least about 1.5×10^6 $M^{-1}s^{-1}$ for binding polypeptide
20 associating with a ligand, thereby having improved therapeutic potency. The method can also involve the step of identifying a binding polypeptide from the one or more different progeny polypeptides having improved therapeutic potency and a k_{on} of at least about 3×10^6 $M^{-1}s^{-1}$,
25 5×10^6 $M^{-1}s^{-1}$, 7×10^6 $M^{-1}s^{-1}$, 9×10^6 $M^{-1}s^{-1}$, 1×10^7 $M^{-1}s^{-1}$, 3×10^7 $M^{-1}s^{-1}$, 5×10^7 $M^{-1}s^{-1}$, 7×10^7 $M^{-1}s^{-1}$ or 9×10^7 $M^{-1}s^{-1}$ or higher for binding polypeptide associating with a ligand.

     A binding polypeptide that associates with a
30 ligand and that is produced from a parent polypeptide

having no measurable association rate with the ligand has an improved association rate. Specifically, a binding polypeptide improved by the methods of the invention having a measurable value for an association rate or k_{on}

5   that is at least 4-fold greater than the limits of detection available to the art constitutes at least a 4-fold increase in association rate or k_{on} for the ligand. Thus, a binding polypeptide that associates with a ligand and that is produced from a parent polypeptide having no

10 measurable association rate with the ligand is understood to have improved therapeutic potency.

The efficacy of a binding polypeptide having improved therapeutic potency can be observed in an individual to be treated or, as an alternative, in an *in*

15 *vivo* model system including, for example, a cell based assay, a tissue based assay, or a whole organism assay. One skilled in the art will know how to determine efficacy in a model according to the conditions specific to the assay and disease under study. For example, the

20 chick chorioallantoic membrane (CAM) assay measures angiogenesis and is a well recognized model for *in vivo* angiogenesis. The assay has been described in detail and has been used to measure neovascularization as well as the neovascularization of tumor tissue (Ausprunk et al.,

25 Am. J. Pathol., 79:597-618 (1975); Ossonski et al. Cancer Res., 40:2300-2309 (1980); Brooks et al. Science, 264:569-571 (1994a) and Brooks et al. Cell, 79:1157-1164 (1994b) which are incorporated herein by reference.

A binding polypeptide identified, determined or

30 produced by the methods of the invention and having improved therapeutic potency can have improved efficacy.

For example, a binding polypeptide having improved
therapeutic potency as identified or determined relative
to a therapeutic control of known efficacy will show
improved efficacy. The methods of the invention can also
5 be used to identify a binding polypeptide having improved
therapeutic potency relative to a therapeutic control for
which efficacy has not been determined as described
previously. Efficacy of a binding polypeptide having
improved therapeutic potency relative to a therapeutic
10 control of unknown efficacy can be tested in an *in vivo*
model as described above. In cases where the efficacy is
less than desired the binding polypeptide can be further
improved by the methods of the invention and re tested in
the *in vivo* model. Repetition of the methods of the
15 invention and testing in an *in vivo* model can be used to
iteratively improve therapeutic potency of a binding
polypeptide until a binding polypeptide yielding the
desired efficacy is produced.

One skilled in the art will recognize that the
20 methods of the invention, which have been exemplified
herein with respect to a binding polypeptide, can be
performed with any binding molecule. In this regard, one
skilled in the art will know that a ligand is a binding
molecule. Accordingly, a binding molecule can be
25 identified and produced according to methods described
herein with respect to identifying and producing a
ligand. Thus the invention provides a method of
determining the therapeutic potency of a binding
molecule. The method can consist of (a) contacting a
30 binding molecule with a ligand; (b) measuring association
rate for binding between the binding molecule and the
ligand, and (c) comparing the association rate for the
binding molecule to an association rate for a therapeutic

control, the relative association rate for the binding
molecule compared to the association rate for the
therapeutic control indicating that the binding molecule
will exhibit a difference in therapeutic potency
5 correlative with the difference between the association
rates. The method can further consist of (d) changing
one or more moiety in the binding molecule and repeating
steps (a) through (c) one or more times. One skilled in
the art will know that methods of combinatorial chemistry
10 can be used in the methods of the invention to produce or
change any binding molecule.

The invention further provides a method of
preventing or treating a virus related disease. The
method can include administering to a patient at risk
15 thereof, or afflicted therewith, a therapeutically
effective amount of an antibody or active fragment
thereof of the invention.

The invention further provides a process for
producing a high potency neutralizing antibody. The
20 process includes the steps of (a) producing a recombinant
antibody, including immunologically active fragments
thereof, having heavy and light chain variable regions
containing one or more framework and/or CDR having
preselected amino acid sequences; (b) screening the
25 recombinant antibodies for high k_{on} when the antibody
reacts in vitro with a selected antigen; and (c)
selecting antibodies with the high k_{on}. The K_a or k_{on} of
the antibody can be any of the values described above.

The invention further provides a method of
30 increasing the potency of an antibody or functional

fragment thereof by selectively changing one or more
amino acids within the variable region framework and/or
CDR regions so as to increase the measured K_a or k_{on}
values. Amino acid changes can be restricted to either
the variable region framework or CDR regions. The K_a or
k_{on} of the antibody prior to or after changing amino acids
can be any of the values described above and can be
increased to at least the above-described values.

EXAMPLE I

Synthesis of focused libraries of
butyrylcholinesterase variants by codon-based
mutagenesis.

This example describes the design and synthesis of
butyrylcholinesterase variant libraries.

A variety of information can be used to focus the
synthesis of the initial libraries of
butyrylcholinesterase variants to discreet regions. For
example, butyrylcholinesterase and Torpedo
acetylcholinesterase (AChE) share a high degree of
homology (53% identity). Furthermore, residues 4 to 534
of Torpedo AChE can be aligned with residues 2 to 532 of
butyrylcholinesterase without deletions or insertions.
The catalytic triad residues (butyrylcholinesterase
residues Ser198, Glu325, and His438) and the intrachain
disulfides are all in the same positions. Due to the
high degree of similarity between these proteins, a
refined 2.8 Å x-ray structure of Torpedo AChE (Sussman et
al., Science 253: 872-879 (1991)) has been used to model

butyrylcholinesterase structure (Harel et al., <u>Proc. Nat. Acad. Sci. USA</u> 89: 10827-10831 (1992)).

Studies with cholinesterases have revealed that the catalytic triad and other residues involved in ligand
5 binding are positioned within a deep, narrow, active-site gorge rich in hydrophobic residues (reviewed in Soreq et al., <u>Trends Biochem. Sci.</u> 17:353-358 (1992)). The sites of seven focused libraries of butyrylcholinesterase variants were selected to include amino acids determined
10 to be lining the active site gorge.

In addition to the structural modeling of butyrylcholinesterase, butyrylcholinesterase biochemical data was integrated into the library design process. For example, characterization of naturally occurring
15 butyrylcholinesterases with altered cocaine hydrolysis activity and site-directed mutagenesis studies provide information regarding amino acid positions and segments important for cocaine hydrolysis activity (reviewed in Schwartz et al., <u>Pharmac. Ther.</u> 67: 283-322(1995)).
20 Moreover, comparison of sequence and cocaine hydrolysis data of butyrylcholinesterases from different species can also provide information regarding regions important for cocaine hydrolysis activity of the molecule based on comparison of the cocaine hydrolysis activities of these
25 butyrylcholinesterases. The A328Y mutant is present in the library and serves as a control to demonstrate the quality of the library synthesis and expression in mammalian cells.

The seven regions of butyrylcholinesterase
selected for focused library synthesis (summarized in
Table 2) span residues that include the 8 hydrophobic
active site gorge residues as well as two of the

5 catalytic triad residues. The integrity of intrachain
disulfide bonds, located between ^{65}Cys-^{92}Cys, ^{252}Cys-^{263}Cys,
and ^{400}Cys-^{519}Cys is maintained to ensure functional
butyrylcholinesterase structure. In addition, putative
glycosylation sites (N-X-S/T) located at residues 17, 57,

10 106, 241, 256, 341, 455, 481, 485, and 486 also are
avoided in the library syntheses. In total, the seven
focused libraries span 79 residues, representing
approximately 14% of the butyrylcholinesterase linear
sequence, and result in the expression of about 1500

15 distinct butyrylcholinesterase variants.

TABLE 2. Summary of Butyrylcholinesterase Libraries

Region	Location	Length	# Variants	Species Diversity
1	68-82	15	285	3
2	110-121	12	228	3
3	194-201	8	152	1
4	224-234	11	209	2
5	277-289	13	247	8
6	327-332	6	114	0
7	429-442	14	266	0
Total		79 13.8%	1,501	

Libraries of nucleic acids corresponding to the
seven regions of human butyrylcholinesterase to be

mutated are synthesized by codon-based mutagenesis, as
described above. Briefly, multiple DNA synthesis columns
are used for synthesizing the oligonucleotides by β-
cyanoethyl phosphoramidite chemistry, as described
5 previously by Glaser et al., *supra*, 1992. In the first
step, trinucleotides encoding for the amino acids of
butyrylcholinesterase are synthesized on one column while
a second column is used to synthesize the trinucleotide
NN(G/T), where N is a mixture of dA, dG, dC, and dT
10 cyanoethyl phosphoramadites. Using the trinucleotide
NN(G/T) results in thorough mutagenesis with minimal
degeneracy, accomplished through the systematic
expression of all twenty amino acids at every position.

Following the synthesis of the first codon, resins
15 from the two columns are mixed together, divided, and
replaced in four columns. By adding additional synthesis
columns for each codon and mixing the column resins,
pools of degenerate oligonucleotides will be segregated
based on the extent of mutagenesis. The resin mixing
20 aspect of codon-based mutagenesis makes the process rapid
and cost-effective because it eliminates the need to
synthesize multiple oligonucleotides. In the present
study, the pool of oligonucleotides encoding single amino
acid mutations are used to synthesize focused
25 butyrylcholinesterase libraries.

The oligonucleotides encoding the
butyrylcholinesterase variants containing a single amino
acid mutation is cloned into the double*lox* targeting
vector using oligonucleotide-directed mutagenesis
30 (Kunkel, *supra*, 1985). To improve the mutagenesis

efficiency and diminish the number of clones expressing wild-type butyrylcholinesterase, the libraries are synthesized in a two-step process. In the first step, the butyrylcholinesterase DNA sequence corresponding to

5   each library site is deleted by hybridization mutagenesis. In the second step, uracil-containing single-stranded DNA for each deletion mutant, one deletion mutant corresponding to each library, is isolated and used as template for synthesis of the

10 libraries by oligonucleotide-directed mutagenesis. This approach has been used routinely for the synthesis of antibody libraries and results in more uniform mutagenesis by removing annealing biases that potentially arise from the differing DNA sequence of the mutagenic

15 oligonucleotides. In addition, the two-step process decreases the frequency of wild-type sequences relative to the variants in the libraries, and consequently makes library screening more efficient by eliminating repetitious screening of clones encoding wild-type

20 butyrylcholinesterase.

The quality of the libraries and the efficiency of mutagenesis is characterized by obtaining DNA sequence from approximately 20 randomly selected clones from each library. The DNA sequences demonstrate that mutagenesis

25 occurs at multiple positions within each library and that multiple amino acids were expressed at each position. Furthermore, DNA sequence of randomly selected clones demonstrates that the libraries contain diverse clones and are not dominated by a few clones.

<u>Optimization of Transfection Parameters for Site-Specific</u>
<u>Integration</u>

Optimization of transfection parameters for
Cre-mediated site-specific integration was achieved
5   utilizing Bleomycin Resistance Protein (BRP) DNA as a
model system.

Cre recombinase is a well-characterized 38-kDa DNA
recombinase (Abremski et al., <u>Cell</u> 32:1301-1311 (1983))
that is both necessary and sufficient for
10 sequence-specific recombination in bacteriophage P1.
Recombination occurs between two 34-base pair loxP
sequences each consisting of two inverted 13-base pair
recombinase recognition sequences that surround a core
region (Sternberg and Hamilton, <u>J. Mol. Biol.</u> 150:467-486
15 (1981a); Sternberg and Hamilton, <u>J. Mol. Biol.</u>,
150:487-507 (1981b)). DNA cleavage and strand exchange
occurs on the top or bottom strand at the edges of the
core region. Cre recombinase also catalyzes
site-specific recombination in eukaryotes, including both
20 yeast (Sauer, <u>Mol. Cell. Biol.</u> 7:2087-2096 (1987)) and
mammalian cells (Sauer and Henderson, <u>Proc. Natl. Acad.</u>
<u>Sci. USA</u>, 85:5166-5170 (1988); Fukushige and Sauer, <u>Proc.</u>
<u>Natl. Acad. Sci. U.S.A.</u> 89:7905-7909 (1992); Bethke and
Sauer, <u>Nuc. Acids Res.</u>, 25:2828-2834 (1997)).

25   Calcium phosphate transfection of 13-1 cells was
previously demonstrated to result in targeted integration
in 1% of the viable cells plated (Bethke and Sauer, <u>Nuc.</u>
<u>Acids Res.</u>, 25:2828-2834 (1997)). Therefore, initial
studies were conducted using calcium phosphate to
30 transfect 13-1 cells with 4 μg pBS185 and 10, 20, 30, or

40 µg of pBS397-f1(+)/BRP. The total level of DNA per
transfection was held constant using unrelated
pBluescript II KS DNA (Stratagene; La Jolla, CA), and
transformants were selected 48 hours later by replating
5 in media containing 400 µg/ml geneticin. Colonies were
counted 10 days later to determine the efficiency of
targeted integration. Optimal targeted integration was
typically observed using 30 µg of targeting vector and 4
µg of Cre recombinase vector pBS185, consistent with the
10 20 µg targeting vector and 5 µg of pBS185 previously
reported (Bethke and Sauer, Nuc. Acids Res., 25:2828-2834
(1997)). The frequency of targeted integration observed
was generally less than 1%. Despite the sensitivity of
the calcium phosphate methodology to the amount of DNA
15 used and the buffer pH, targeted integration efficiencies
observed were sufficient to express the protein
libraries.

As shown in Table 3, several cell lines as well as
other transfection methods were also characterized. In
20 general, lipid-mediated transfection methods are more
efficient than methods that alter the chemical
environment, such as calcium phosphate and DEAE-dextran
transfection. In addition, lipid-mediated transfections
are less affected by contaminants in the DNA
25 preparations, salt concentration, and pH and thus
generally provide more reproducible results (Felgner et
al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)).
Consequently, a formulation of the neutral lipid dioleoyl
phosphatidylethanolamine and a cationic lipid, termed
30 GenePORTER transfection reagent (Gene Therapy Systems;
San Diego, CA), was evaluated as an alternative
transfection approach. Briefly, endotoxin-free DNA was

prepared for both the targeting vector pBS397-f1(+)/BRP and the Cre recombinase vector pBS185 using the EndoFree Plasmid Maxi kit (QIAGEN; Valencia, CA). Next, 5 µg pBS185 and varying amounts of pBS397-f1(+)/BRP were

5   diluted in serum-free medium and mixed with the GenePORTER transfection reagent. The DNA/lipid mixture was then added to a 60-70% confluent monolayer of 13-1 cells consisting of approximately 5×10^5 cells/100-mm dish and incubated at 37°C. Five hours later, fetal calf

10   serum was added to 10%, and the next day the transfection media was removed and replaced with fresh media.

Transfection of the cells with variable quantities of the targeting vector yielded targeted integration efficiencies ranging from 0.1% to 1.0%, with the optimal

15   targeted integration efficiency observed using 5 µg each of the targeting vector and the Cre recombinase vector. Lipid-based transfection of the 13-1 host cells under the optimized conditions resulted in 0.5% targeted integration efficiency being consistently observed. A

20   0.5% targeted integration is slightly less than the previously reported 1.0% efficiency (Bethke and Sauer, <u>Nuc. Acids Res.</u>, 25:2828-2834 (1997)), and is sufficient to express large protein libraries and allows expressing libraries of protein variants in mammalian cells.

TABLE 3. Expression of a single butyrylcholinesterase variant per cell using either stable or transient cell transfection.

Cell Line	Expression	Integration Method	Integration? (PCR)	Integration? (Activity)
NIH3T3 (13-1)	Transient (lipid-based)	N/A	N/A	Transient, very low activity
NIH3T3 (13-1)	Stable	Cre recombinase	Yes	No measurable activity
CHO	Transient (lipid-based)	N/A	N/A	Transient, measurable activity (colorimetric and cocaine hydrolysis)
293	Transient (lipid-based)	N/A	N/A	Transient, measurable activity (colorimetric and cocaine hydrolysis)
293	Stable	Flp recombinase	Yes	Measurable activity (colorimetric and cocaine hydrolysis)

These results demonstrate optimization of transfection conditions for targeted insertion in NlH3T3 13-1 cells. Conditions for a simple, lipid-based transfection method that required a small amount of DNA and generated reproducible 0.5% targeting efficiency were established.

Expression of butyrylcholinesterase variant libraries in
mammalian cells

      Each of the seven libraries of
butyrylcholinesterase variants are transformed into a
5 host mammalian cell line using the doublelox targeting
vector and the optimized transfection conditions
described above. Following Cre-mediated transformation
the host cells are plated at limiting dilutions to
isolate distinct clones in a 96-well format. Cells with
10 the butyrylcholinesterase variants integrated in the
Cre/lox targeting site are selected with geneticin.
Subsequently, the DNA encoding butyrylcholinesterase
variants from 20-30 randomly selected clones from each
library are sequenced and analyzed as described above.
15 Briefly, total cellular DNA is isolated from about 10^4
cells of each clone of interest using DNeasy Tissue Kits
(Qiagen, Valencia, CA). Next, the butyrylcholinesterase
gene is amplified using Pfu Turbo DNA polymerase
(Stratagene; La Jolla, CA) and an aliquot of the PCR
20 product is then used for sequencing the DNA encoding
butyrylcholinesterase variants from randomly selected
clones by the fluorescent dideoxynucleotide termination
method (Perkin-Elmer, Norwalk, CT) using a nested
oligonucleotide primer.

25   As described previously, the sequencing
demonstrates uniform introduction of the library and the
diversity of mammalian transformants resembles the
diversity of the library in the doublelox targeting
vector following transformation of bacteria.

Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.